CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma

Takumi Kumai, Toshihiro Nagato, Hiroya Kobayashi, Yuki Komabayashi, Seigo Ueda, Kan Kishibe, Takayuki Ohkuri, Miki Takahara, Esteban Celis, Yasuaki Harabuchi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Nasal natural killer/T-cell lymphoma (NNKTL) is associated with Epstein–Barr virus and has a poor prognosis because of local invasion and/or multiple dissemination. Various chemokines play a role in tumor proliferation and invasion, and chemokine receptors including the C-C chemokine receptor 4 (CCR4) are recognized as potential targets for treating hematologic malignancies. The aim of the present study was to determine whether specific chemokines are produced by NNKTL. We compared chemokine expression patterns in culture supernatants of NNKTL cell lines with those of other lymphoma or leukemia cell lines using chemokine protein array and ELISA. Chemokine (C-C motif) ligand (CCL) 17 and CCL22 were highly produced by NNKTL cell lines as compared to the other cell lines. In addition, CCL17 and CCL22 were readily observed in the sera of NNKTL patients. The levels of these chemokines were significantly higher in patients than in healthy controls. Furthermore, we detected the expression of CCR4 (the receptor for CCL17 and CCL22) on the surface of NNKTL cell lines and in tissues of NNKTL patients. Anti-CCR4 monoclonal antibody (mAb) efficiently induced antibody-dependent cellular cytotoxicity mediated by natural killer cells against NNKTL cell lines. Our results suggest that CCL17 and CCL22 may be important factors in the development of NNKTL and open up the possibility of immunotherapy of this lymphoma using anti-CCR4 mAb.

Original languageEnglish (US)
Pages (from-to)697-705
Number of pages9
JournalCancer Immunology, Immunotherapy
Volume64
Issue number6
DOIs
StatePublished - Jun 6 2015

Fingerprint

C Chemokines
Natural Killer T-Cells
T-Cell Lymphoma
Chemokine Receptors
Nose
Chemokines
Cell Line
CC Chemokines
Therapeutics
Lymphoma
Monoclonal Antibodies
Protein Array Analysis
Hematologic Neoplasms
Natural Killer Cells
Immunotherapy
Leukemia
Enzyme-Linked Immunosorbent Assay

Keywords

  • CCL17
  • CCL22
  • CCR4
  • Chemokine
  • Nasal NK/T-cell lymphoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma. / Kumai, Takumi; Nagato, Toshihiro; Kobayashi, Hiroya; Komabayashi, Yuki; Ueda, Seigo; Kishibe, Kan; Ohkuri, Takayuki; Takahara, Miki; Celis, Esteban; Harabuchi, Yasuaki.

In: Cancer Immunology, Immunotherapy, Vol. 64, No. 6, 06.06.2015, p. 697-705.

Research output: Contribution to journalArticle

Kumai, T, Nagato, T, Kobayashi, H, Komabayashi, Y, Ueda, S, Kishibe, K, Ohkuri, T, Takahara, M, Celis, E & Harabuchi, Y 2015, 'CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma', Cancer Immunology, Immunotherapy, vol. 64, no. 6, pp. 697-705. https://doi.org/10.1007/s00262-015-1675-7
Kumai, Takumi ; Nagato, Toshihiro ; Kobayashi, Hiroya ; Komabayashi, Yuki ; Ueda, Seigo ; Kishibe, Kan ; Ohkuri, Takayuki ; Takahara, Miki ; Celis, Esteban ; Harabuchi, Yasuaki. / CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma. In: Cancer Immunology, Immunotherapy. 2015 ; Vol. 64, No. 6. pp. 697-705.
@article{d5adba9e07e844a4aa69889c3eac4d5d,
title = "CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma",
abstract = "Nasal natural killer/T-cell lymphoma (NNKTL) is associated with Epstein–Barr virus and has a poor prognosis because of local invasion and/or multiple dissemination. Various chemokines play a role in tumor proliferation and invasion, and chemokine receptors including the C-C chemokine receptor 4 (CCR4) are recognized as potential targets for treating hematologic malignancies. The aim of the present study was to determine whether specific chemokines are produced by NNKTL. We compared chemokine expression patterns in culture supernatants of NNKTL cell lines with those of other lymphoma or leukemia cell lines using chemokine protein array and ELISA. Chemokine (C-C motif) ligand (CCL) 17 and CCL22 were highly produced by NNKTL cell lines as compared to the other cell lines. In addition, CCL17 and CCL22 were readily observed in the sera of NNKTL patients. The levels of these chemokines were significantly higher in patients than in healthy controls. Furthermore, we detected the expression of CCR4 (the receptor for CCL17 and CCL22) on the surface of NNKTL cell lines and in tissues of NNKTL patients. Anti-CCR4 monoclonal antibody (mAb) efficiently induced antibody-dependent cellular cytotoxicity mediated by natural killer cells against NNKTL cell lines. Our results suggest that CCL17 and CCL22 may be important factors in the development of NNKTL and open up the possibility of immunotherapy of this lymphoma using anti-CCR4 mAb.",
keywords = "CCL17, CCL22, CCR4, Chemokine, Nasal NK/T-cell lymphoma",
author = "Takumi Kumai and Toshihiro Nagato and Hiroya Kobayashi and Yuki Komabayashi and Seigo Ueda and Kan Kishibe and Takayuki Ohkuri and Miki Takahara and Esteban Celis and Yasuaki Harabuchi",
year = "2015",
month = "6",
day = "6",
doi = "10.1007/s00262-015-1675-7",
language = "English (US)",
volume = "64",
pages = "697--705",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "6",

}

TY - JOUR

T1 - CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma

AU - Kumai, Takumi

AU - Nagato, Toshihiro

AU - Kobayashi, Hiroya

AU - Komabayashi, Yuki

AU - Ueda, Seigo

AU - Kishibe, Kan

AU - Ohkuri, Takayuki

AU - Takahara, Miki

AU - Celis, Esteban

AU - Harabuchi, Yasuaki

PY - 2015/6/6

Y1 - 2015/6/6

N2 - Nasal natural killer/T-cell lymphoma (NNKTL) is associated with Epstein–Barr virus and has a poor prognosis because of local invasion and/or multiple dissemination. Various chemokines play a role in tumor proliferation and invasion, and chemokine receptors including the C-C chemokine receptor 4 (CCR4) are recognized as potential targets for treating hematologic malignancies. The aim of the present study was to determine whether specific chemokines are produced by NNKTL. We compared chemokine expression patterns in culture supernatants of NNKTL cell lines with those of other lymphoma or leukemia cell lines using chemokine protein array and ELISA. Chemokine (C-C motif) ligand (CCL) 17 and CCL22 were highly produced by NNKTL cell lines as compared to the other cell lines. In addition, CCL17 and CCL22 were readily observed in the sera of NNKTL patients. The levels of these chemokines were significantly higher in patients than in healthy controls. Furthermore, we detected the expression of CCR4 (the receptor for CCL17 and CCL22) on the surface of NNKTL cell lines and in tissues of NNKTL patients. Anti-CCR4 monoclonal antibody (mAb) efficiently induced antibody-dependent cellular cytotoxicity mediated by natural killer cells against NNKTL cell lines. Our results suggest that CCL17 and CCL22 may be important factors in the development of NNKTL and open up the possibility of immunotherapy of this lymphoma using anti-CCR4 mAb.

AB - Nasal natural killer/T-cell lymphoma (NNKTL) is associated with Epstein–Barr virus and has a poor prognosis because of local invasion and/or multiple dissemination. Various chemokines play a role in tumor proliferation and invasion, and chemokine receptors including the C-C chemokine receptor 4 (CCR4) are recognized as potential targets for treating hematologic malignancies. The aim of the present study was to determine whether specific chemokines are produced by NNKTL. We compared chemokine expression patterns in culture supernatants of NNKTL cell lines with those of other lymphoma or leukemia cell lines using chemokine protein array and ELISA. Chemokine (C-C motif) ligand (CCL) 17 and CCL22 were highly produced by NNKTL cell lines as compared to the other cell lines. In addition, CCL17 and CCL22 were readily observed in the sera of NNKTL patients. The levels of these chemokines were significantly higher in patients than in healthy controls. Furthermore, we detected the expression of CCR4 (the receptor for CCL17 and CCL22) on the surface of NNKTL cell lines and in tissues of NNKTL patients. Anti-CCR4 monoclonal antibody (mAb) efficiently induced antibody-dependent cellular cytotoxicity mediated by natural killer cells against NNKTL cell lines. Our results suggest that CCL17 and CCL22 may be important factors in the development of NNKTL and open up the possibility of immunotherapy of this lymphoma using anti-CCR4 mAb.

KW - CCL17

KW - CCL22

KW - CCR4

KW - Chemokine

KW - Nasal NK/T-cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84930413876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930413876&partnerID=8YFLogxK

U2 - 10.1007/s00262-015-1675-7

DO - 10.1007/s00262-015-1675-7

M3 - Article

VL - 64

SP - 697

EP - 705

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 6

ER -